Dec 9, 2025 12:48PM Sidoti Events, LLC's Year-End Virtual Investor Conference

Dec 9, 2025 12:48PM Sidoti Events, LLC's Year-End Virtual Investor Conference

Nov 10, 2025 04:55PM Precision BioSciences (DTIL) Halted, News Pending

Oct 9, 2025 07:02AM Precision BioSciences publishes ARCUS gene editing research findings

Sep 8, 2025 07:02AM Precision BioSciences receives U.S. patent for hepatitis B gene therapy

Aug 7, 2025 08:06AM Precision BioSciences (DTIL) Misses Q2 EPS by 213c

Jul 23, 2025 07:02AM Precision BioSciences gets FDA orphan drug status for DMD treatment

Jul 17, 2025 12:10PM Precision BioSciences gets FDA orphan drug designations for DMD treatment

Jul 16, 2025 07:02AM Precision BioSciences reports positive preclinical data for DMD gene therapy

Jun 25, 2025 07:03AM Precision BioSciences (DTIL) Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Jun 18, 2025 12:15PM CRISPR Therapeutics (CRSP) gains on continued chatter

Jun 17, 2025 11:28AM Verve Therapeutics takeover has 'positive readthrough' for gene editing space - BMO Capital

May 15, 2025 04:23PM Precision BioSciences (DTIL) Misses Q1 EPS by 221c

Apr 15, 2025 07:01AM Precision BioSciences (DTIL) Receives U.S. FDA Fast Track Designation for PBGENE-HBV

Mar 26, 2025 07:09AM Precision BioSciences (DTIL) Misses Q4 EPS by 222c

Mar 20, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Precision BioSciences Inc. (DTIL)

Mar 17, 2025 07:02AM Precision BioSciences (DTIL) Announces Clearance of Investigational New Drug Application by the U.S. FDA

Feb 20, 2025 06:53AM H.C. Wainwright Reiterates Buy Rating on Precision BioSciences Inc. (DTIL)

Feb 19, 2025 07:01AM Precision BioSciences (DTIL) Announces Initial Safety and Antiviral Activity of PBGENE-HBV

Jan 29, 2025 07:10AM Precision BioSciences (DTIL) Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Jan 10, 2025 07:53AM Precision BioSciences (DTIL) Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Jan 10, 2025 05:10AM BMO Capital Upgrades Precision BioSciences Inc. (DTIL) to Outperform

Dec 18, 2024 07:01AM Precision BioSciences (DTIL) Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial

Nov 4, 2024 02:22PM BMO Capital Reiterates Market Perform Rating on Precision BioSciences Inc. (DTIL)

Nov 4, 2024 07:43AM Precision BioSciences (DTIL) Misses Q3 EPS by 225c

Oct 24, 2024 04:15PM Precision BioSciences (DTIL) Presents Preclinical Data Highlighting the Capability of ARCUS

Oct 24, 2024 08:47AM Precision BioSciences (DTIL) Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Sep 30, 2024 07:02AM Precision BioSciences (DTIL) Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B

Sep 12, 2024 07:15AM Precision BioSciences (DTIL) Announces Leadership Changes

Sep 3, 2024 07:01AM Precision BioSciences (DTIL) Receives $13M in Proceeds from Imugene Convertible Note Maturity

Jul 1, 2024 07:02AM Precision BioSciences (DTIL) to Join Russell Microcap Index